Drug Profile
Timothy grass extract immunotherapy - Stallergenes Greer plc
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Greer Laboratories
- Developer Stallergenes Greer plc
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Seasonal allergic rhinitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Seasonal-allergic-rhinitis in USA (Sublingual, Drops)
- 04 Dec 2007 Greer initiates enrolment in a phase I trial for allergic rhinitis in high risk patients in USA